Portal de Periódicos da CAPES

Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta‐analysis

2020; Wiley; Volume: 34; Issue: 1 Linguagem: Inglês

10.1111/dth.14487

1529-8019

Surjit Singh, Saurabh Singh, Abisha Thangaswamy, Pugazhenthan Thangaraju, Shoban Babu Varthya,

Autoimmune Bullous Skin Diseases

Dermatologic TherapyVolume 34, Issue 1 e14487 REVIEW ARTICLE Efficacy and safety of Risankizumab in moderate to severe psoriasis: A systematic review and meta-analysis Surjit Singh, Surjit Singh orcid.org/0000-0002-8990-3235 Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, IndiaSearch for more papers by this authorSaurabh Singh, Saurabh Singh orcid.org/0000-0003-4356-6883 Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, IndiaSearch for more papers by this authorAbisha Thangaswamy, Abisha Thangaswamy Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, IndiaSearch for more papers by this authorPugazhenthan Thangaraju, Pugazhenthan Thangaraju orcid.org/0000-0002-4090-2004 Department of Pharmacology, All India Institute of Medical Sciences, Raipur, IndiaSearch for more papers by this authorShoban Babu Varthya, Corresponding Author Shoban Babu Varthya drshobanpgimer@gmail.com orcid.org/0000-0002-7163-0400 Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India Correspondence Shoban Babu Varthya, Assistant Professor, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur. Email: drshobanpgimer@gmail.comSearch for more papers by this author Surjit Singh, Surjit Singh orcid.org/0000-0002-8990-3235 Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, IndiaSearch for more papers by this authorSaurabh Singh, Saurabh Singh orcid.org/0000-0003-4356-6883 Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, IndiaSearch for more papers by this authorAbisha Thangaswamy, Abisha Thangaswamy Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, IndiaSearch for more papers by this authorPugazhenthan Thangaraju, Pugazhenthan Thangaraju orcid.org/0000-0002-4090-2004 Department of Pharmacology, All India Institute of Medical Sciences, Raipur, IndiaSearch for more papers by this authorShoban Babu Varthya, Corresponding Author Shoban Babu Varthya drshobanpgimer@gmail.com orcid.org/0000-0002-7163-0400 Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India Correspondence Shoban Babu Varthya, Assistant Professor, Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur. Email: drshobanpgimer@gmail.comSearch for more papers by this author First published: 02 November 2020 https://doi.org/10.1111/dth.14487Citations: 8 Surjit Singh and Shoban Babu Varthya have contributed equally to this study. Funding information: Evidence Prime Inc.; McMaster University Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Monoclonal antibodies are explored for their therapeutic potential in Psoriasis. To evaluate Risankizumab in the moderate to severe psoriasis with regard to efficacy, tolerability, and safety PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and clinicaltrials.gov, databases were searched for relevant RCTs. The reference lists of relevant publications were also scanned manually to identify any further studies not indexed in the searched databases. Only RCT aiming to evaluate the role of Risankizumab in the treatment of moderate to severe psoriasis were considered eligible for this systematic review. Intervention group was patients taking Risankizumab and placebo or other monoclonal antibody was considered as control group. Cochrane review manager 5 (RevMan) version 5.3 was used for data synthesis and meta-analysis. Quality assessment of included randomized controlled trials was done with Cochrane Collaboration risk of bias assessment tool, version 2.0 (ROB-2). Overall Grading of evidence for study objectives was performed with GRADE Pro GDT software. A total of seven studies were included in analysis with total of 1533 and 710 patients in Risankizumab and standard care groups, respectively. Statistically significant increase in percentage of individual achieving PASI90 (OR = 11.01 (95% CI = 8.67-13.99), DLQI-01 (OR = 6.95 (95% CI = 5.53-8.75), sPGA-01 (OR = 14.22 (95% CI = 11.10-18.22); sPGA-0 (OR = 6.39 (95% CI = 4.79-8.54) in risankizumab group as compared with control, with high quality of evidence. Increased risk of infections with risankizumab as compared with placebo (OR = 1.44 [95% CI = 1.13-1.83], high quality evidence), while no difference in SAE among two groups. Analysis of all outcome data from RCTs. In the light of evidence from systematic review on effectiveness of Risankizumab, we propose treatment with risankizumab for psoriasis patients not responding to available treatment. CONFLICT OF INTEREST The authors declare no potential conflict of interest. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. Citing Literature Supporting Information Filename Description dth14487-sup-0001-FigureS1.tifTIFF image, 718 KB Supplementary Figure 1S ROB-2: Risk of bias in RCT evaluating Risankizumab for Psoriasis (Weighted Summary plot) dth14487-sup-0002-FigureS2.tifTIFF image, 1.8 MB Supplementary Figure 2S Funnel plot depicting publication bias for studies included in the review Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Volume34, Issue1January/February 2021e14487 RelatedInformation